Reem Karmali MD

Hematologic Oncology

Associate Professor, Division of Hematology/ Oncology, Northwestern University Feinberg School of Medicine, Robert H Lurie Cancer Center

Join to view full profile

676 N Saint Clair StSte 850Chicago, IL 60611
Phone+1 312-695-0990
Fax+1 312-695-1106

Dr. Karmali is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Karmali's full profile Already have an account?

Summary

Dr. Reem Karmali is an oncologist in Chicago, IL and is affiliated with Northwestern Memorial Hospital. She received her medical degree from University of Western Ontario and has been in practice 11 years. She specializes in hematologic oncology.

Education & Training

Rush University Medical CenterFellowship, Hematology and Medical Oncology, 2012
Rush University Medical CenterResidency, Internal Medicine, 2009
University of Western OntarioClass of 2006

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

IL State Medical License 2009 - 2029
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification PowerChart (Clinical), Cerner Corporation, 2014-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2014-2017

Clinical Trials

Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
COMPLETED
PHASE2
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 02
TERMINATED
PHASE3
Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies Start of enrollment: 2018 Mar 29
COMPLETED
PHASE1, PHASE2

Publications & Presentations

PubMed

Second Line CD19 CAR-T vs Platinum Salvage and Autologous Stem Cell Transplant for Primary Mediastinal B-Cell Lymphoma.
Xi Yang, Henry Dumke, Swetha Kambhampati Thiruvengadam, Christine Argao, Joseph G Schroers-Martin
Blood Advances. 2026-08-20
Secondary Cardiac Lymphoma Causing High-Grade Heart Block: Pacemaker Considerations in an Unpredictable Clinical Course.
John Sollee, Graham Peigh, Kaustubha Patil, Albert Lin, Nausheen Akhter
JACC. Case Reports. 2026-08-19
Measuring group‑ and individual‑level change of FACIT- fatigue, NFLymSI-18 and PROMIS fatigue measures (4a, 7a and 13a) in lymphoma.
Maja Kuharic, Kimberly A Webster, Anne R Zola, Maria E Corona, Elijah A Patten
Journal of Patient-Reported Outcomes. 2026-07-19

Abstracts/Posters

Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma
Reem Karmali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
Reem Karmali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas
Reem Karmali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Ibrutinib maintenance following induction for untreated mantle cell lymphoma (MCL): Initial safety report.
2019 ASCO Annual Meeting - 6/1/2019
Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

$Confronting Knowledge Gaps Concerning Relapsed/Refractory Follicular Lymphoma$
Confronting Knowledge Gaps Concerning Relapsed/Refractory Follicular LymphomaJune 22nd, 2022
Dr. Karmali on Challenges in MCLJuly 10th, 2019
Emerging Data Help Fine-Tune Treatment Strategies in Hodgkin Lymphoma and Follicular LymphomaApril 10th, 2019